El año pasado, ANI Pharmaceuticals Inc generó 384.11M USD en su segmento con mejor rendimiento, Sales of generic pharmaceutical products. United States realizó la mayor aportación, representando 852.44M USD el año pasado. Para el último trimestre, ANI Pharmaceuticals Inc reportó unos ingresos de 117.13M USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, Sales of Cortrophin Gel. United States aportó los mayores ingresos, alcanzando los 182.40M USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Sales of generic pharmaceutical products

Sales of rare disease pharmaceutical products

Sales of Cortrophin Gel

Sales of branded pharmaceutical products

Generic pharmaceutical products

Brand

Royalty and other

Sales of contract manufactured products

Royalties from licensing agreements

Product development services

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

Sales of generic pharmaceutical products

384.11M(33.22%)

301.00M(43.17%)

269.45M(27.67%)

210.12M(66.41%)

143.57M(66.43%)

147.26M(70.64%)

Sales of rare disease pharmaceutical products

347.78M(30.08%)

198.09M(28.41%)

112.12M(11.52%)

41.69M(13.18%)

--(--)

Sales of Cortrophin Gel

347.78M(30.08%)

198.09M(28.41%)

112.12M(11.52%)

--(--)

Sales of branded pharmaceutical products

76.61M(6.63%)

--(--)

105.25M(10.81%)

39.46M(12.47%)

47.56M(22.01%)

47.96M(23.01%)

Generic pharmaceutical products

--(--)

269.45M(27.67%)

--(--)

Brand

--(--)

85.38M(8.77%)

--(--)

Royalty and other

--(--)

19.87M(2.04%)

--(--)

Sales of contract manufactured products

--(--)

16.11M(5.09%)

10.04M(4.65%)

9.22M(4.42%)

Royalties from licensing agreements

--(--)

5.37M(1.70%)

11.79M(5.46%)

1.40M(0.67%)

Product development services

--(--)

2.95M(0.93%)

1.31M(0.61%)

1.86M(0.89%)

Other

--(--)

693.00K(0.22%)

1.86M(0.86%)

783.00K(0.38%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

International

Canada

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

852.44M(96.50%)

604.99M(98.47%)

486.25M(99.88%)

312.43M(98.75%)

211.89M(98.04%)

202.88M(97.32%)

199.66M(96.67%)

196.89M(97.67%)

International

30.92M(3.50%)

9.39M(1.53%)

--(--)

Canada

--(--)

565.00K(0.12%)

3.96M(1.25%)

4.24M(1.96%)

5.59M(2.68%)

6.88M(3.33%)

4.69M(2.33%)